Rocio del Valle Fernandez

Dr. Rocio del Valle Fernandez


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Tuberculosis
Verified
Journal Article
Closed access
SSSilvana Virginia Spinelli
Silvana Virginia Spinelli
RFRocio del Valle Fernandez
Rocio del Valle Fernandez
LZLuciana Zoff
Luciana Zoff
BBBettina Bongiovanni
Bettina Bongiovanni
ADAriana Díaz
Ariana Díaz
OBOscar A. Bottasso
Oscar A. Bottasso

12 November 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
ESEric Schneider
Eric Schneider
JHJohn A. Hangasky
John A. Hangasky
RFRocio del Valle Fernandez
Rocio del Valle Fernandez
GAGary W. Ashley
Gary W. Ashley
DSDaniel V Santi
Daniel V Santi
The objective of this work was to develop a long-acting form of the lipidated peptide semaglutide that can be administered to humans once-monthly. Semaglutide was attached to hydrogel microspheres by a cleavable linker with an expected in vivo release half-life of about 1 mo. After a single subcutaneous dose, the pharmacokinetic parameters of released semaglutide and bodyweight loss were determined in mice, and results were used to estimate the dosing and pharmacokinetics of the released semaglutide in humans. The in vivo half-life of released semaglutide was ~36 d, and a single dose in diet-induced obese mice resulted in a lean-sparing body weight loss of 20% over 1 mo, statistically the same as semaglutide dosed twice daily. Simulations indicated the microsphere-semaglutide would permit once-monthly administration in humans; moreover, it could maintain the therapeutic minimum concentration (C min ) of once-weekly semaglutide with only 75% of the once-weekly maximum concentration (C max ), a feature that could reduce adverse side effects or allow higher dosing. The same approach should enable the conversion of other lipidated peptides from once-weekly to once-monthly administration.

21 January 2026 in Research Square
Verified
Preprint
Open access
PDF file
DSDaniel Santi
Daniel Santi
SHSujin Hoshi
Sujin Hoshi
ESEric Schneider
Eric Schneider
AOAkiko Oota-Ishigaki
Akiko Oota-Ishigaki
TOTetsuo Oshika
Tetsuo Oshika
GHGuillermo Hails
Guillermo Hails
Intravitreal (IVT) injection is a crucial drug delivery method for ocular diseases, but it requires frequent administration due to short drug half-lives. This study presents a novel approach to long-acting IVT therapy using biodegradable tetra-PEG hydrogel microspheres (MSs) as drug carriers. These MSs, approximately 50 μm in diameter, are designed with β-eliminative cleavable linkers that allow for controlled drug release and programmed carrier degradation. The study demonstrates that MSs can persist in the vitreous without clearing for very long periods – perhaps years – controlled by the rate of degradation programmed into the microspheres. Drug surrogates tethered to MSs via releasable linkers exhibited release half-lives of up to 60 days, consistent with the employed linkers. By incorporating cleavable linkers in MS crosslinks with different degradation rates, the time to reverse gelation (tRG) into clearable tetra-PEG monomers was successfully programmed, with one gel studied showing degradation within 8 weeks, and another within 12 months post-injection. Tolerability studies conducted in rabbits over 14 months, encompassing MS biodegradation, showed stable intraocular pressure, maintained lens transparency, and no significant changes in retinal structures or signs of inflammation. The MS technology offers several additional advantageous features, including excellent injectability through a 29G needle, autoclave sterilization capability, and applicability to various drug types. Importantly, proof-of-concept studies demonstrated sustained release of the clinically important anti-VEGF antibody bevacizumab in rabbits over extended periods, and maintenance of therapeutic concentrations significantly longer than conventional bolus injection. This "plug-and-play" technology allows for easy assembly of IVT delivery systems with predictable and tunable drug half-lives and dosing frequencies, addressing the need for extended dosing intervals in ocular drug delivery.

15 July 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RFRocio del Valle Fernandez
Rocio del Valle Fernandez
GHGuillermo Hails
Guillermo Hails
JHJohn A. Hangasky
John A. Hangasky
GAGary W. Ashley
Gary W. Ashley
DSDaniel V Santi
Daniel V Santi
Background/Objectives: Interleukin-15 (IL-15) is a promising immunotherapeutic cytokine, but its short half-life limits clinical utility. We developed a stable PEGylated receptor-linker IL-15 agonist (PEG-RLI) to improve pharmacokinetic properties while preserving biological activity and antitumor efficacy. Methods: PEG-RLI was synthesized by site-specific N-terminal conjugation of a 40 kDa methoxy polyethylene glycol (MeOPEG) to RLI. The conjugate was characterized for purity and receptor agonism. Pharmacokinetics were evaluated in mice, and pharmacodynamic effects on NK cells and CD8+ T cell subsets were assessed. Antitumor activity was tested in CT26 tumor-bearing mice alone and in combination with anti-PD-1 therapy. Results: PEGylation preserved RLI agonistic activity and extended its mouse half-life from approximately 3 h to approximately 15 h. PEG-RLI induced robust expansion of NK cells and CD8+ T cells, with preferential enrichment of CD8+ T cells and CD44hiCD8+ T cells. In CT26 solid tumors, PEG-RLI enhanced the antitumor efficacy of anti-PD-1 treatment. Conclusions: Stable PEGylation improved the pharmacokinetic profile of RLI while maintaining potent immunostimulatory activity. PEG-RLI preferentially expanded CD8+ T cells and showed promising efficacy with immune checkpoint blockade, supporting further development as a differentiated IL-15-based immunotherapeutic.